Independent Living REIT plc, intends to float on the Premium Segment of the Main Market. The Company’s investment objective is to address the shortage of high-quality supported housing, delivering capital growth and inflation-linked income returns for its investors whilst providing a fair deal for society through savings for the UK taxpayer, and improved outcomes for residents. Raising £150m. Expected 4 October 2022.
The Sustainable Farmland Trust PLC, intends to float on the Premium Segment of the Main Market. The Company invests in a diversified portfolio of farmland and related agriculture-focused assets predominantly located in the US. Raising £200m. Timing TBC.
Welkin China Private Equity, newly established closed-ended investment company dedicated to investing in unquoted Chinese companies, intends to join the Premium Segment of the Main Market. The Company is targeting a raise of up to US$300m.
Georgina Energy, focusing on the exploration, development and monetisation of helium, hydrogen and hydrocarbon interests located in Australia intends to join AIM. Georgina Energy has two principal onshore interests: (1) Mount Winter Prospect in the Amadeus Basin in Northern Australia, which the Company has a right to earn an initial 75% interest; (2) Hussar Prospect, 100% owned by the Company, located in the Officer Basin in Western Australia. Expected late September.
Altona Rare Earths, the AQSE-listed mining exploration company focused on rare earth elements projects in Africa, intends to join the Main Market. The trading of its ordinary shares on the AQSE Growth Market will be cancelled simultaneously and its EPIC will be changed from AQSE:ANR to REE. Conditionally raised £1.1m. Expected late September.
Atlantic Lithium 43p £253.8m (ALL.L)
The African-focussed lithium exploration and development company targeting to deliver Ghana’s first lithium mine, confirms that the Company has today been admitted to the Official List of the Australian Securities Exchange (ASX). The Company’s shares will commence trading on ASX under the ticker ‘A11’ at 12:00PM AEST on Monday, 26 September 2022. Shares will continue to trade on the AIM market.
Inspiration Healthcare Group 82p £55.9m (IHC.L)
The global medical technology company announces that it has received an order worth approximately £600k for the supply of SLE ventilators and associated consumables from its Japanese distributor for delivery before the end of this financial year. The SLE ventilators are high-specification, sophisticated infant ventilators offering a range of conventional modes with additional options for non-invasive ventilation, high frequency oscillation ventilation and high flow oxygen therapy. Japan has been a successful market for SLE prior to the acquisition in 2020.
Keywords Studio £23.13 £1,787.2m (KWS.L)
The international technical and creative services provider to the global video games industry, announces that it has entered into a conditional agreement to acquire Smoking Gun Interactive Inc. Keywords will pay a maximum amount of CAD$40m, comprised of initial cash consideration of CAD$16m, the equivalent of CAD$4m in new ordinary shares to be issued within 30 days of completion, and up to CAD$20m, in a mix of cash and new ordinary shares based on milestones. Smoking Gun is expected to grow and deliver EBITDA of around CAD$6m.
Kibo Energy* 0.17 £5.2m (KIBO.L)
The renewable energy focused development company, announces that it has signed a definitive share purchase agreement to acquire a 100% interest in a waste reception, Anaerobic Digestor and CHP (combined hear ant power) project (Southport project) at Merseyside, U.K. This will be a 10MW installed CHP plant plus 2MW battery storage. Kibo will pay £600k (consisting of £250k in cash and £350k in Kibo’s ordinary shares) to acquire 100% of the issued share capital of Shankley Biogas Ltd, the project developer, constructor and operator. Shankley Biogas has negotiated a power purchase agreement and a gas purchase agreement with a blue-chip buyer. The forecasted project net present value (6%) is c. £47m and the estimated capital required is c. £35m.
LBG Media 78p £161m (LBG.L)
The UK-based multi-brand, multi-channel digital youth publisher, reports its results for the six months ended 30 June 2022. Revenue increased 8% to £24.8m (HY21: £23.0m). Adjusted EBITDA fell by 78% to £1.6m (HY21: £7.3m), and LBG moved to a statutory loss before tax of £1,9m (HY21: £5.6m profit), due to investment in staff and cancelled physical marketing events amid Covid-19 restrictions. Following the investment in people, its global audience grew by 62m people to over 315m (HY21: 253m), with 35.8bn content views in the period, up 38% on the prior year. Management believes results for the full year will be broadly in line with market expectations.
MyHealthChecked 1.8p £14.2m (MHC.L)
The consumer home-testing healthcare company, announces its unaudited results for the six months ended 30 June 2022, which exceeded management expectations. Revenue increased 197% to £9.8m (H1 2021: £3.3m) largely driven by distribution of COVID lateral flow tests to pharmacy retailers and direct to consumers following the Government’s cessation of free lateral flow testing. Adjusted EBITDA improved to £0.37m (H1 2021: loss of £0.20m), as did gross profit reporting £1.5m (H1 2021: £1.1m). In the period FlowFlex™ COVID-19 lateral flow test kits were distributed into 2 top pharmacy retailers and the new portfolio of DNA wellness test panels was developed, built and launched.
SDX Energy 9.9p £20.3m (SDX.L)
The EMEA-focused oil and gas company, announces that Michael Doyle intends to step down as Chairman and leave the Board with immediate effect. Tim Linacre, currently an independent non-executive director has been appointed Interim Chairman effective immediately. Michael will continue to act as a consultant to the Company until 31st January 2023. The Board also announce the appointment of Krzysztof Zielicki as a Non-Executive Director with immediate effect. Krzysztof has over four decades of experience in the oil and gas industry.
Surgical Innovations 1.7p £15.4m (SUN.L)
The designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery, reports its unaudited results for the six-month period ended 30 June 2022. Thanks to strong sales in the UK and APAC (particularly Japan), revenues increased 28% on prior year to £5.41m and amounted to 106% of the comparable pre-pandemic period in 2019. Adjusted EBITDA was £0.29m, up 38% year-on-year. Revenue in July and August were approx. 113% year-on-year. Sales backorder are £0.7m. The company continues to trade profitably at the adjusted EBITDA level.
WANdisco 446.7p £297.1m (WAND.L)
The data activation platform announces that it has signed a contract with a value of $25m with a top ten global communications company. Following this Customer win, the Company expects record bookings for FY2022, significantly ahead of current market expectations. As a Commit-to-Consume contract, revenue will be recognised over time and has the potential to grow further as its data requirements grow. This is the fourth consecutive contract with the Customer, following the $11.6m order announced earlier this year. The cumulative contracts from this Customer total $39.3m during 2022.
Warpaint 131.5p £100.9m (W7L.L)
The specialist supplier of colour cosmetics and owner of the W7 and Technic brands, announces its unaudited results for the six months ended 30 June 2022. Group sales increased by 37% to £25.2m in H1 2022 (H1 2021: £18.4m). International revenue increased by 55% to £14.8m (H1 2021: £9.5m), while UK revenue increased by 17% to £10.4m (H1 2021: £8.9m). Statutory profit from operations grew 11.6x to £3.5m (H1 2021: £0.3m). Online sales continued to grow in both the UK and the US, with an increase of 44% in e-commerce sales compared to H1 2021. The group’s financial performance is expected to be second half weighted and management are confident performance will continue for the remainder of the year and beyond.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
